PHENOM
6.6.2024 13:01:27 CEST | Business Wire | Press release
Phenom today released the third annual European Edition of its eighth annual State of Candidate Experience Benchmarks Report, which analyzes and ranks Fortune 500 companies based on how they are attracting, engaging and converting talent throughout the candidate journey. The European audit report revealed the majority of organisations are failing to leverage data and personalised, contextual information to support candidates throughout their journey to find the right work — for example, 96% did not ask about skills to match candidates with related job openings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606262890/en/
Phenom’s third annual European Edition of its eighth annual State of Candidate Experience Benchmarks Report revealed the majority of organisations are failing to leverage data and personalised, contextual information to support candidates throughout their journey to find the right work. For example, 96% did not ask about skills to match candidates with related job openings. The audit report analyzes and ranks Fortune 500 companies based on how they are attracting, engaging and converting talent throughout the candidate journey. (Graphic: Business Wire)
With these opportunities to improve considered, the report also highlights notable year-over-year progress when leveraging AI, automation and talent marketing strategies to enhance experiences for candidates — including a 529% increase in featuring dynamically curated content, including information about the company, open jobs, benefits, culture, employee testimonials and interview tips.
Opportunities to Improve Matching Candidates with the Right Work
- 97% do not have social media content embedded in the job seeker experience
- 96% do not provide job recommendations based on experience level or job titles
- 95% do not have job recommendations based on a created profile
- 89% do not automatically detect the candidate’s geographic location to suggest relevant, nearby jobs
- 20% decrease of having a chatbot on career site
How the European 100 is Building Better Candidate Journeys with AI and Engaging Content
- 123% increase in displaying video content featuring employee testimonials that showcase company culture and reasons to work there
- 87% provide an easy authentication process for returning users
- 79% have content in multiple languages tailored to specific locations
- 32% increase in featuring a job cart or ability to easily favorite jobs
- 10% increase in having a clearly visible and accessible “apply” button
Over the past year, the European labor market has been heavily influenced by supply chain disruptions affecting regional supplies, demographic shifts causing labor shortages, and the prioritisation of DE&I in the workplace — among other things.
Simply publishing a career site is no longer enough; talent acquisition teams, talent marketers, and recruiters must invest in the right AI and personalization technology, content and talent marketing strategies, employer branding and user experience to establish indispensable connections that convert job seekers into applicants.
Recommendations to Improve the Candidate Experience
Phenom’s 2024 European Edition of the State of Candidate Experience report includes prescriptive guidance for organisations seeking to improve how they attract, engage and convert talent with automation and intelligence.
-
Attracting and engaging top talent faster. Candidates continue to search for their next job across many disparate channels. Organisations must adopt a comprehensive talent marketing approach that makes jobs widely accessible. Consistent branding and a clear value proposition should be reflected in every step of the journey.
-
Delivering a one-of-a-kind experience. Candidates are unlikely to apply if it is difficult to find information when researching a potential employer. AI and automation can personalise every touchpoint and streamline the discovery of relevant opportunities.
- Turning passive job seekers into new hires with a seamless process. Candidates no longer complete job applications that are time and labor intensive. Organisations must introduce a fast and frictionless job discovery and application process, spanning no more than 3 minutes for high-volume roles.
“It’s clear the competition for top talent is not won by a standalone career site or chatbot — job seekers are engaging with companies across a multitude of channels,” said John Harrington, Sr. Director, Product Marketing at Phenom. “Savvy organisations are keeping up by leveraging intelligence and automation to deliver personalised candidate experiences across every touchpoint, ultimately improving the way they engage and convert a broader talent pool.”
With Phenom, candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimize hiring processes, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIS easily integrates existing HR tech to create a holistic infrastructure.
To read the full 2024 report and European 100 company rankings, get the report here.
Organisations not featured in the report can request their own complimentary candidate experience audit here.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIS — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, One-Way Interviews, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (4 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606262890/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
